Zobrazeno 1 - 10
of 79
pro vyhledávání: ''
Publikováno v:
Investigational New Drugs
Summary Background There is a need to establish an effective neoadjuvant therapy for soft tissue sarcomas (STSs). We previously showed that apatinib, administered in combination with doxorubicin-based chemotherapy, improves the efficacy of treatment.
Autor:
Pete Weber, Fuxin Shi, John Soglia, John Keilty, Heather Wolff, Ryan McCarthy, Jason Kropp, Vissia Viglietta, Yong Ren, Hu Qi-Ying
Publikováno v:
Investigational New Drugs
SummaryCisplatin is a widely used chemotherapy for the treatment of certain solid tumors. Ototoxicity and subsequent permanent hearing loss remain a serious dose-limiting side effect associated with cisplatin treatment. To date, no therapies have bee
Autor:
An K.L. Reyners, Daan J Touw, K Esther Broekman, Marieke A J Hof, Hans W. Nijman, Jourik A. Gietema, Joop D. Lefrandt, Mathilde Jalving
Publikováno v:
Investigational new drugs, 38(5), 1454-1462. SPRINGER
Investigational New Drugs
Investigational New Drugs
SummaryBackground Metformin use is associated with reduced cancer risk in epidemiological studies and has preclinical anti-cancer activity in ovarian cancer models. The primary objective of this phase I study was to determine the recommended phase II
Autor:
Prateek Mendiratta, Ruby Gupta, Matthew M. Cooney, Robert Dreicer, Jorge A. Garcia, Pedro C. Barata
Publikováno v:
Investigational New Drugs. 37:331-337
Background Mammalian target of rapamycin (mTOR) pathway and angiogenesis through vascular endothelial growth factor (VEGF) have been shown to play important roles in prostate cancer progression. Preclinical data in prostate cancer has suggested the p
Publikováno v:
Investigational new drugs. 39(2)
Background Nanoparticle albumin-bound paclitaxel (nab-PTX) and docetaxel (DOC) both demonstrated favorable efficacy as neoadjuvant therapy in breast cancer. We retrospectively evaluated the efficacy and safety of nab-PTX-based chemotherapy (nPBC) and
Autor:
Koichi Azuma, Norikazu Matsuo, Takaaki Tokito, Akihiko Kawahara, Tomoaki Hoshino, Hidenobu Ishii
Publikováno v:
Investigational new drugs. 39(1)
Although immune checkpoint inhibitors have improved the survival of small cell lung cancer (SCLC) patients, their efficacy in SCLC patients who relapsed after systemic chemotherapy is unclear. This retrospective study aimed to investigate the utility
Autor:
Chengyuan Qian, Jinlu Shan, Mingfang Xu, Xuemei Li, Cheng-Xiong Xu, Hao Luo, Yan Feng, Mengxia Li, Liang Zhang, Yuxiao Wang, Xueqin Yang, Dong Wang, Nan Dai
Publikováno v:
Investigational New Drugs
SummaryBackground Overexpression of apurinic/apyrimidinic endonuclease 1 (APE1) is an important cause of poor chemotherapeutic efficacy in advanced non-small cell lung cancer (NSCLC) patients. Gossypol, a new inhibitor of APE1, in combination with do
Autor:
Catherine Brezault, Olivier Mir, Marie Bréchon, Johann Dreanic, Marie-Anne Guillaumot, François Goldwasser, Marie Dior, Romain Coriat, B Brieau
Publikováno v:
Investigational New Drugs. 36:156-162
Background The prognosis of patients with metastatic carcinoma of the biliary tract (mBTC) is poor and a systemic therapy with gemcitabine and platinum-based is the gold standard. The addition of bevacizumab to the chemotherapy might increase patient
Autor:
Makoto Maemondo, Yuta Okamura, Yuichi Tambo, Ryo Koyama, Toshiaki Takahashi, Makoto Nishio, Tomoya Kawaguchi, Terufumi Kato, Yasutsuna Sasaki, Hiroshi Nokihara, Hiroshi Sakai, Takashi Seto, Shinji Atagi, Kazuhiko Nakagawa, Osamu Nakamura, Tomohide Tamura, Naoyuki Nogami, Yukio Hosomi
Publikováno v:
Investigational New Drugs. 35:217-226
Objectives To determine the recommended dose and efficacy/safety of docetaxel combined with resminostat (DR) in non-small cell lung cancer (NSCLC) patients with previous platinum-based chemotherapy. Materials and Methods A multicenter, open-label, ph
Autor:
Lin Lin, Xuezhi Hao, Hua Bai, Rui Wan, Xingsheng Hu, Jianchun Duan, Xin Wang, Yutao Liu, Junling Li, Hongyu Wang, Zhijie Wang, Yan Wang, Jie Wang
Publikováno v:
Investigational new drugs. 37(4)
Background This phase I trial was primarily conducted to determine the maximum tolerated dose (MTD) of apatinib combined with docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR who have failed to first-line platinum-based chemothe